This book fulfils an urgent need for an updated text on pediatricpsychopharmacology. It takes a unique approach in discussing recentfindings within the context of current issues, including economicand political ones. The book covers the emerging question oftreating children who do not yet meet diagnostic criteria forpsychosis, e.g, schizophrenia or bipolar disorder, but who aredeemed to be at high risk. This is an active area of debate: suchchildren are being treated in certain centers, while others rejectthis completely. The book addresses the antidepressant controversy,the placebo response and unique strategies for delineating this,and ways to optimize the differential between active medication andplacebo. It reviews the impact of recent American Heart Associationguidelines for monitoring children on stimulants and otherpsychotropics. It adheres closely to DSM-IV diagnostic criteriathroughout. The book describes the use of newly approved drugs suchas Lexapro for treating adolescent depression and the novelcompound Intuniv. It covers the TADS and CAMS studies, whichevaluated the use of SSRIs alone and in combination with cognitivebehavioral therapy for adolescent depression. Other topics includetreatment of bipolar disorders, the increasing popularity ofgeneric equivalents, combination pharmacotherapy and the potentialdangers of psychotropic medications.
* Third edition of the first ever book published on pediatricpsychopharmacology from renowned editors.
* Incorporates current developments with regard to SSRIs, theirindications and their safety issues, including possible associatedsuicidal behavior.
* Addresses concerns about cardiovascular side effects of the newstimulant medications available, and compares to other FDA-approvedmedications for ADHD.
* Features many tables, figures and pictorials, making it highlyaccessible and reader friendly.